GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Capex-to-Revenue

Tissue Regenix Group (LSE:TRX) Capex-to-Revenue : 0.03 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Tissue Regenix Group's Capital Expenditure for the six months ended in Dec. 2023 was £-0.33 Mil. Its Revenue for the six months ended in Dec. 2023 was £12.16 Mil.

Hence, Tissue Regenix Group's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.03.


Tissue Regenix Group Capex-to-Revenue Historical Data

The historical data trend for Tissue Regenix Group's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Capex-to-Revenue Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.11 0.10 0.05 0.03

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.05 0.03 0.03

Competitive Comparison of Tissue Regenix Group's Capex-to-Revenue

For the Biotechnology subindustry, Tissue Regenix Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Capex-to-Revenue falls into.



Tissue Regenix Group Capex-to-Revenue Calculation

Tissue Regenix Group's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.682) / 23.299
=0.03

Tissue Regenix Group's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.333) / 12.162
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tissue Regenix Group  (LSE:TRX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Tissue Regenix Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.

Tissue Regenix Group (LSE:TRX) Headlines

From GuruFocus

TanGold Announces Board and Management Change

By GlobeNewswire GlobeNewswire 01-21-2021

Buckreef Gold Mine Development Update

By GlobeNewswire GlobeNewswire 09-12-2019

Tanzanian Royalty Announces the Sale of Common Shares of $885,734

By GlobeNewswire GlobeNewswire 01-13-2019